SEC Tracker
Get the app

Quince Therapeutics IRLA

Quince Therapeutics approves new stock plans

Form
8-K
Filed
Importance
Routine
  1. Approved 2026 Equity Incentive Plan with 821,872 initial shares
  2. Approved 2026 Employee Stock Purchase Plan with 142,045 initial shares
  3. Increased authorized common stock from 250M to 275M shares

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Quince Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Veru VERU public float $64M, Mar 31, 2025, over 18 months old
  2. Lifevantage LFVN public float $64M, Dec 31, 2025
  3. Whitehawk Therapeutics WHWK public float $65M, Jun 30, 2025
  4. Medicinova MNOV public float $62M, Jun 30, 2025
  5. Corbus Pharmaceuticals Holdings CRBP public float $68M, Jun 30, 2025